Advisor Group Holdings, Inc. Aligos Therapeutics, Inc. Transaction History

Advisor Group Holdings, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.35 - $1.07 $1,924 - $5,885	5,500 New	5,500 $1,000
Q1 2022 May 04, 2022	BUY	$2.08 - $12.2 $7,280 - $42,700	3,500 Added 77.78%	8,000 $17,000
Q3 2021 Nov 05, 2021	BUY	$14.57 - $17.72 $65,565 - $79,740	4,500 New	4,500 $70,000

227K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $1.28B
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.